metabolic bone disease remodeling sequences

91
Metabolic Bone Diseases The remodeling sequence Vinod Naneria Consultant orthopaedic surgeon Choithram Hospital & Research Centre Indore , India

Upload: vinod-naneria

Post on 27-May-2015

1.977 views

Category:

Health & Medicine


0 download

DESCRIPTION

a comprehensive details of functioning of BMU

TRANSCRIPT

Page 1: Metabolic bone disease remodeling sequences

Metabolic Bone DiseasesThe remodeling sequence

Vinod NaneriaConsultant orthopaedic surgeon

Choithram Hospital & Research Centre

Indore , India

Page 2: Metabolic bone disease remodeling sequences

Basics – Remodeling stages

• There are more than 25 recognized steps involved in one cycle of remodeling.

• BMU Cells activation, • Resorption of Matrix and Minerals –2 -3 Wks.• Re activation of Bone forming unit or reversal, • New bone formation• Mineralization start after 2 weeks • Maximum mineralization 3 - 12 months • Maturation takes up to 3 years.

Page 3: Metabolic bone disease remodeling sequences

Basics…

• Bone loss through osteoclast-mediated bone resorption and bone replacement through osteoblast-mediated bone formation are tightly coupled processes.

• Resorbed bone is precisely replaced in location and amount by new bone.

Page 4: Metabolic bone disease remodeling sequences

Basics…

• Osteoblasts direct osteoclasts differentiation. • Osteoclasts play a crucial role in the

promotion of bone formation.• Osteoclast conditioned medium stimulates

human mesenchymal stem (hMS) cell migration and differentiation toward the osteoblast lineage as measured by mineralized nodule formation in vitro.

Page 5: Metabolic bone disease remodeling sequences

Bone remodeling - sequences

1. Micro fracture – Mechanical stress

2. Signals to brain,

3. Activation of stem cells from mesenchymal origin,

4. Maturation of pre osteoblasts,

5. Maturation of pre osteoclasts,

6. Rank-L secretion by osteoblast,

7. Fusion of pre osteoclast in to a multi nucleated mature Osteoclast,

8. Osteoclast adherence to hydroxyapatite crystals,

9. Formation of sealing mechanism,

10.Formation of podosomes or Ruffled border

Page 6: Metabolic bone disease remodeling sequences

11. Matrix absorption,

12. Mineral absorption

13. Trans cytoplasmic calcium transportation to ECF,

14. Ph regulation at ruffled border,

15. Formation of lacunae,

16. Reversal to bone formation

17. Cross talk with mature osteoblasts, (coupling)

18. Separation/ migration or apoptosis of osteoclasts,

19. Role of osteoprotegerin,

20. Migration of osteoblasts in the lacunae,

21. Secretion of new matrix,

22. Role of Sclerostatins,

23. Mineralization of matrix,

24. Role of Inorganic phosphates in regulation of mineralization,

25. Maturation of bone architecture,

Page 7: Metabolic bone disease remodeling sequences

Micro-crackSequence of bone

repair

Page 8: Metabolic bone disease remodeling sequences
Page 9: Metabolic bone disease remodeling sequences

Quiescent stage

• This is a quiescent bone surface. The embedded osteocytes in the bone is actively secreting “Sclerostin”, a protein which inhibits Wnt-signaling in cells near the surface. The preosteoclasts are circulating in the blood vessels.

• Wnt – siganaling is the key for osteogenesis.

Page 10: Metabolic bone disease remodeling sequences

The photograph is showing a micro-crack due to sudden stress.

Osteocytes are alive

Page 11: Metabolic bone disease remodeling sequences

Osteocytes• Osteocytes are the

mechanosensory cells of bone, play a pivotal role in functional adaptation of bone.

• Periosteocytic space filled with Extracellular fluid.

• Sensation of mechanical load is perceived as fluid shear stress on bone surface.

• apoptosis of Osteocytes generate signals that activate osteoclast resorption.

Page 12: Metabolic bone disease remodeling sequences

The osteocyte functions as a mechanoreceptor that translates mechanical stimuli into biochemical signals.

The surrounding osteocytes detect strain and start secreting growth factors, prostaglandins and nitric oxide.

The expression of PGE2 by loaded osteocytes and the consequent activation of the cAMP/PKA pathway, together with stabilization of β-catenin, may permit cross talk with the canonical Wnt/β-catenin pathway, the activation of which is increased by the load-dependent reduction of the expression of DKK1 and of sclerostin.

Detection of the crack - micro fracture

Page 13: Metabolic bone disease remodeling sequences

These signal pathways, as well as TGF-β and BMP expression, stimulate the differentiation and activity of osteoblasts, reduce their apoptosis, and enhance bone formation.

The expressions of MEPE, FGF-23 and DMP-1 further contribute to the osteocytic control of bone metabolism. Periosteocytic osteolysis, if definitively demonstrated, would constitute another fundamental function of osteocytes.

Detection of the crack - micro fracture

Page 14: Metabolic bone disease remodeling sequences

Due to crack, osteocytes near the surface goes in to apoptosis.

Page 15: Metabolic bone disease remodeling sequences

Crack

Death of Osteocytes

Page 16: Metabolic bone disease remodeling sequences

Canopy • The lining cells pull away from the bone matrix and

form a canopy which mergers with the blood vessels. Some of the canopy cells look like pre-osteoblasts.

• The stromal cells are now released from the inhibitory effect of Sclerostin and are exposed to the factors like IL-1. They generate pre-osteoblasts. Stromal cells also secrete M-CSF ( macrophage colony stimulating factor) which help generate pre-osteoclast.

Page 17: Metabolic bone disease remodeling sequences

Canopy

Page 18: Metabolic bone disease remodeling sequences

Sclerostin• Sclerostin produced by the osteocytes • It blocks the mineralization beyond lining cells.• Defects in the SOST gene -absence or reduced

production of Sclerostin, causes Sclerosteosis and Van Buchem diseases, hypertrophic bones which are fracture resistant.

• Sclerostin binds to LRP5 and antagonizes the Wnt pathway.

Page 19: Metabolic bone disease remodeling sequences
Page 20: Metabolic bone disease remodeling sequences

Preosteoblast proliferation

Page 21: Metabolic bone disease remodeling sequences

Pre Osteoblast

• The pre-osteoblasts proliferate and secrete more factors, such as Wnt, ILs, and BMPs.

• All these factors are responsible for maturation of osteoblasts.

Page 22: Metabolic bone disease remodeling sequences

Wnt – Osteoblast maturation• Signals originating from members of the wnt

(wingless-type mouse mammary tumor virus integration site) family of paracrine factors are important. Paracrine is a “inter cellular communication” system.

• The central role of Wnt signaling is in regulating osteoblast lineage specification, expansion, and terminal differentiation.

• Humans and mice missing a wnt-family co-receptor, LRP5 (lipoprotein receptor–related protein 5), have osteoporosis. Remarkably, humans with an overactive form of LPR5 have increased bone mass.

Page 23: Metabolic bone disease remodeling sequences

+ promote

- inhibits

Osteogenesis

Chondrogenesis Adipogenesis

Page 24: Metabolic bone disease remodeling sequences

Wnt/beta-catenin signaling is involved in bone biology.

Wnt autocrine loop mediates the induction of alkaline phosphatase and mineralization by BMP-2 in pre-osteoblastic cells.

LRP5 acts as a co-receptor for Wnt proteins, and plays crucial role for Wnt signaling in bone biology.

In mesenchymal cells, only Wnt's capable of stabilizing beta-catenin induced the expression of alkaline phosphatase (ALP).

Osteoblast maturationBMP-2 + ALP + Mineralization + Wnt autocrine loop

Page 25: Metabolic bone disease remodeling sequences

Canonical beta-catenin signaling is a responsible factor for inhibition of Wnt-3 activity.

The induction of ALP by Wnt is independent of morphogenetic proteins and does not require de novo protein synthesis.

Blocking Wnt/LRP5 signaling or protein synthesis inhibited the ability of both BMP-2 and Shh to induce ALP in mesenchymal cells.

BMP-2 enhanced Wntl and Wnt3a expression in cells. The capacity of BMP-2 and Shh to induce ALP relies on Wnt expression and the Wnt/LRP5 signaling cascade. Moreover the effects of BMP-2 on extracellular matrix mineralization by osteoblasts are mediated, at least in part, by the induction of a Wnt autocrine/paracrine loop.

BMP-2 + ALP + Mineralization + Wnt autocrine loop

Page 26: Metabolic bone disease remodeling sequences

Rank-L secretion

Page 27: Metabolic bone disease remodeling sequences

RANK =Receptor activator for nuclear factor kb

• The pre-osteoblasts start to express RANK-L on their surfaces.

• The pre-osteoclasts have RANK receptors on their surface. For maturation of pre-osteoclast into osteoclast RANK-L play a crucial role.

• RANK is a member of TNF family of receptors expressed mainly on cells of macrophages / monocytes lineage such as Pre-osteoclasts

• When this receptor binds its specific ligand (RANK-L) through cell- cell contact , osteoclastogenesis is initiated.

Page 28: Metabolic bone disease remodeling sequences

RANK-L

• RANK-L is produced by and expressed on the cell membranes of osteoblast & marrow stromal cells

• Its major role is stimulation of osteoclast formation , fusion, differentiation, activation , survival.

• In chemistry, a ligand is either an atom, ion, or molecule (functional group) that binds to a central metal to produce a coordination complex.

Page 29: Metabolic bone disease remodeling sequences

The discovery and characterization of RANK-L, RANK, and OPG and subsequent studies have changed the concepts of bone and calcium metabolism, have led to a detailed understanding of the pathogenesis of metabolic bone diseases, and may form the basis of innovative therapeutic strategies.

With the appearance of RANK-L, the pre-osteoclasts start fusing with each other and maturing into a functional multi-nucleated “Osteoclast” cell.

RANK & RANK - L

Page 30: Metabolic bone disease remodeling sequences

RANK – L + RANKOsteoclast Maturation

Page 31: Metabolic bone disease remodeling sequences

Resorption Cycle

• From the formation of functional osteoclasts to resorption of bone matrix and excretion of degraded products into extra cellular spaces, it needs a step wise “resorption cycle”.

• This cycle starts with the death of osteocytes due to stress or strain and ends with the reinstallation of “osteoblasts” in the resorption pits.

Page 32: Metabolic bone disease remodeling sequences

Resorption Cycle

• The non-mineralized osteoid covers the mineralized bone matrix in vivo, preventing its resorption by osteoclasts. Thus, before osteoclasts can begin the actual resorption in vivo, the osteoid must be dissolved or mineralized, after which osteoclasts can attach to the mineralized matrix and initiate bone resorption. Proteases released by osteoblastic cells have been shown to be responsible for dissolving the osteoid and thereby inducing osteoclastic resorption and determining its location

Page 33: Metabolic bone disease remodeling sequences

Osteopontin (OPN) is a highly phosphorylated sialoprotein that is a prominent component of the mineralized extracellular matrices of bones. OPN is characterized by the presence of a polyaspartic acid sequence and sites of Ser/Thr phosphorylation that mediate hydroxyapatite binding, and a highly conserved RGD motif that mediates cell attachment/signaling.

Osteopontin (OPN) was expressed in murine wild-type osteoclasts, localized to the basolateral, clear zone, and ruffled border membranes, and deposited in the resorption pits during bone resorption. OPN is a required osteoclast motility factor mediating surface expression of CD44 receptor. Also, OPN secreted into the resorption pit is required for adhesion during bone resorption.

Osteopontin (OPN) – adhesion to matrix

Page 34: Metabolic bone disease remodeling sequences

It has been shown that OPN drives IL-17 production; OPN is over expressed in a variety of cancers, including lung cancer, breast cancer, colorectal cancer, stomach cancer, ovarian cancer, melanoma and mesothelioma; OPN contributes both glomerulonephritis and tubulointestinal nephritis; and OPN is found in atheromatous plaques within arteries.

Thus, manipulation of plasma OPN levels may be useful in the treatment of autoimmune diseases, cancer metastasis, osteoporosis and some forms of stress. Research has implicated osteopontin in excessive scar-forming and a gel has been developed to inhibit its effect.

Osteopontin (OPN) – adhesion to matrix

Page 35: Metabolic bone disease remodeling sequences

In the sealing zone, also called as clear zone, the cell membrane forms a tight attachment to the bone surface, thereby isolating the resorption lacuna from the extracellular fluid and permitting the maintenance of a specific microenvironment in the lacuna. The sealing zone is seen as an electro-dense area free of organelles and it has a striated appearance in electron microscopy, with alternating dark and light areas orientated perpendicular to the bone surface, consisting of bundles of actin filaments. Ruffled border (RB) is a highly convoluted plasma membrane domain under which the actual bone resorption takes place.

Osteoclast - Sealing Zone

Page 36: Metabolic bone disease remodeling sequences

Sealing zone surrounds the RB, thus defining the outlines of the resorption lacuna. Acidic intracellular vesicles fuse to the cell membrane facing the bone matrix, thereby forming RB membrane. RB does not fit to any type of previously described plasma membrane domains, because it has both lysosomal and endosomal features. Bone degradation occurs in the extracellular space between the bone matrix and the RB, which is called the resorption lacuna. In the middle of the basolateral membrane is the fourth membrane domain, the functional secretory domain (FSD), which appears when matrix degradation is started.

Sealing Zone & Ruffled Border (RB)

Page 37: Metabolic bone disease remodeling sequences

Osteoclastic membrane domains

• Polarization• Sealing zone or clear zone (SZ)• Ruffled border (RB)• Basolateral membrane (BLM)• Functional secretory domain (FSZ)

Page 38: Metabolic bone disease remodeling sequences

Mature Osteoclast

Page 39: Metabolic bone disease remodeling sequences

Normal Multinucleated Osteoclast Tightly Adherent to Bone

Page 40: Metabolic bone disease remodeling sequences

Normal Multinucleated Osteoclast tightly adherent to bone. The interface with the bone perimeter is marked by a ruffled or striated border of micro-villi (white arrow), which is best visualized by electron microscopy.

The osteoclast–bone interface creates a unique extracellular microenvironment, ideal for bone resorption.

The lysosome-rich vacuolar zone (black arrow), composed of acidified vesicles containing Cathepsin K and matrix metalloproteinases, is distinctly visualized. Polarized away from the bone surface are six nuclei with prominent nucleoli.

Page 41: Metabolic bone disease remodeling sequences

Sealing mechanismA number of cell surface glycoproteins have been identified as intercellular adhesion molecules.These are classified into three major molecular families, the Immunoglobulin (Ig) super-family, the Integrin superfamily, and the Cadherin family.

Integrins have been identified as a family of cell surface receptors that recognize extracellular matrices. Integrins are adhesion molecules that mediate cell attachment to the substrate by binding to an arginine-glycine-aspartic acid (RGD) consensus sequence in their ligands .

Page 42: Metabolic bone disease remodeling sequences

Sealing mechanism - Vitronectin receptor

• Osteoclasts express two members of Integrin super family, the Vitronectin receptor αvβ 3 and α2β 1.

• Vitronectin receptor mediates the tight attachment of osteoclasts to bone matrix and that Osteopontin, a bone matrix component containing the RGD sequence is the ligand of the osteoclast Vitronectin receptor.

• VNR has also been shown to be located only in the ruffled border, basolateral membranes and intracellular vesicles of osteoclasts, but missing from the area of the tight sealing zone .

Page 43: Metabolic bone disease remodeling sequences

Vitronectin receptor

• The first indications of the importance of vitronectin receptor came from the experiments in which monoclonal antibodies against osteoclasts, later identified as anti-vitronectin receptor antibodies, inhibited osteoclastic bone resorption in vitro.

• It has been shown that peptides containing the RGD sequence potentially inhibit bone resorption.

• It has also been shown that osteoclasts adhere in vitro to a wide range of RGD peptide containing proteins, including bone sialoproteins, via a β

3 integrin.

Page 44: Metabolic bone disease remodeling sequences

Bone Absorption

• The osteoclasts bind to the bone matrix with Integrins.

• They secrete acid and Cathepsin K at its ruffled border to absorb the bone.

• Bone re-absorption at this spot take about 2 weeks.

• Bone – derived growth factors IGF & TGF-b are released.

Page 45: Metabolic bone disease remodeling sequences

Bone Absorption

Page 46: Metabolic bone disease remodeling sequences

• The hallmark of the resorbing surface is the appearance of a Howship’s or resorption lacuna. • In cancellous bone, cavities are up to 50m in depth towards its center. • In cortical bone, the tunnel is parallel with the long axis of the bone and is about 2,5 mm long and 200 m in diameter. • The resorption phase takes about two-three weeks.

The Howship’s Lacuna

Page 47: Metabolic bone disease remodeling sequences

Bone absorption

• At this stage osteoclast actually transforms in to multi-functional unit with three different types of cytoplasmic membranes. A ruffled border secrete acid and dissolve the bone matrix (organic and inorganic both), the Basolateral border maintains the intracellular Ph by active exchange of ions and prevent the damage to intra cellular structures. The third Functional border becomes an excretory membrane. It disperse the large vesicles containing material adsorbed by the ruff border in to extra cellular spaces by trans-cytoplasmic route

Page 48: Metabolic bone disease remodeling sequences

Functional Osteoclast

Page 49: Metabolic bone disease remodeling sequences

• Schematic view of a bone resorbing osteoclast. Extensive vesicular trafficking involving several specific membrane domains is a hallmark of actively resorbing cells. BL, basolateral domain (blue); FSD, functional secretory domain (red); SZ, sealing zone (green); RB, ruffled border (black). Brown vesicles illustrate vesicular pathways from the trans-Golgi network and the basolateral membrane to RB, and yellow vesicles illustrate the transcytotic route from the RB to the FSD. Vesicular pathways from the trans-Golgi network to the apical (black vesicles) and basolateral (blue vesicles) membrane domains are shown. HA, haemagglutinin; VSV-G, vesicular stomatitis virus G protein. RL, resorption lacuna (white).

Page 50: Metabolic bone disease remodeling sequences

In this photo you can actually see the contact between an osteoclast. Osteoclasts produce hydrogen ions that acidify and dissolve the bone surface, as well as hydrolytic enzymes

osteoclast at breakfast, basically shows an osteoclast with some similarities to a snail- leaving behind not a trail of mucus but rather of eaten bone.

Page 51: Metabolic bone disease remodeling sequences

osteoclast undergoes apoptosis

Page 52: Metabolic bone disease remodeling sequences

Resorbing osteoclasts are highly polarized cells. osteoclasts contain not only the sealing zone but also at least three other specialized membrane domains: a ruffled border, a functional secretory domain and a basolateral membrane.

Resorption requires cellular activities: migration of the osteoclast to the resorption site, its attachment to bone, polarization and formation of new membrane domains, dissolution of hydroxyapatite, degradation of organic matrix, removal of degradation products from the resorption lacuna, and finally either apoptosis of the osteoclasts or their return to the non-resorbing stage. αvb3 is highly expressed in osteoclasts and is found both at the plasma membrane and in various intracellular vacuoles.

The integrin could play a role both in adhesion and migration of osteoclasts and in endocytosis of resorption products. High amounts of αvb3 are present at the ruffled border and denatured type I collagen has a high affinity for αvb3.

RESORPTION CYCLE - Summary

Page 53: Metabolic bone disease remodeling sequences

The ruffled border is a resorbing organelle, and it is formed by fusion of intracellular acidic vesicles with the region of plasma membrane facing the bone. During this fusion process much internal membrane is transferred, and forms long, finger-like projections that penetrate the bone matrix. Several late endosomal markers, such as Rab7, Vtype H-ATPase and lgp110, are densely concentrated at the ruffled border. Basolateral domain of the resorbing osteoclast is divided into two distinct domains and that the centrally located domain is an equivalent to the apical membrane of epithelial cells. the basal membrane represents homogeneous membrane area.

The Ruffled Border

Page 54: Metabolic bone disease remodeling sequences

The Ruffled Border

• The apical domain (also known as the functional secretory domain) in this unexpected site might function as a site for exocytosis of resorbed and transcytosed matrix-degradation products.

• Before proteolytic enzymes can reach and degrade collageneous bone matrix, tightly packed hydroxyapatite crystals must be dissolved.

• The dissolution of mineral occurs by targeted secretion of HCl through the ruffled border into the resorption lacuna. This is an extracellular space between the ruffled border membrane and the bone matrix, and is sealed from the extracellular fluid by the sealing zone.

Page 55: Metabolic bone disease remodeling sequences

The low pH in the resorption lacuna is achieved by the action of ATP-consuming vacuolar proton pumps both at the ruffled border membrane and in intracellular vacuoles. Acidic extracellular compartments lie beneath the resorbing cells and also that there is a high density of acidic intracellular compartments inside non-resorbing Osteoclasts . Concomitant with the appearance of the ruffled border, the number of intracellular acidic compartments promptly decreases as the vesicles containing proton pumps are transported to the ruffled border.

Ion channel pumps

Page 56: Metabolic bone disease remodeling sequences

Ion channel pumps

• Resorption lacuna is further acidified by direct secretion of protons through the ruffled border. Protons for the proton pump are produced by cytoplasmic Carbonic anhydrase II, high levels of which are synthesized in osteoclasts.

• Excess cytoplasmic bicarbonate is removed via the chloride-bicarbonate exchanger located in the basolateral membrane. There is a high number of chloride channels in the ruffled border, which allows a flow of chloride anions into the resorption lacuna to maintain electroneutrality.

Page 57: Metabolic bone disease remodeling sequences

After solubilization of the mineral phase, several proteolytic enzymes degrade the organic bone matrix.

Two major classes of proteolytic enzymes, lysosomal cysteine proteinases and matrix metalloproteinases (MMPs).

The high levels both of expression of MMP-9 (gelatinase B) and Cathepsin K and of their secretion into the resorption lacuna suggest that these enzymes play a central role in the resorption process.

MMP-9 (gelatinase B) and Cathepsin K

Page 58: Metabolic bone disease remodeling sequences

Excretion - Transcytosis• After matrix degradation, the degradation products are

removed from the resorption lacuna through a transcytotic vesicular pathway from the ruffled border to the functional secretory domain, where they are liberated into the extracellular space. Tartrate-resistant acid phosphatase (TRAP), is localised in the transcytotic vesicles of resorbing osteoclasts, and that it can generate highly destructive reactive oxygen species able to destroy collagen.

• This activity, together with the co-localisation of TRAP and collagen fragments in transcytotic vesicles, suggests that TRAP functions in further destruction of matrix-degradation products in the transcytotic vesicles.

Page 59: Metabolic bone disease remodeling sequences

Transcytosis

Osteoclasts can remove large amounts of degradation products via transcytosis without detaching from the bone surface and loosing the tight attachment of the sealing zone to the bone surface.

The transcytosis route provides a possibility for osteoclasts to further process the endocytosed degradation products intracellularly during their passage through the cell. The bone-specific enzyme TRAP is located in cytoplasmic vesicles, which fuse to the transcytotic vesicles and participates in destroying the endocytosed material in the transcytotic route .

Page 60: Metabolic bone disease remodeling sequences

Osteoclasts resorb bone by attaching to the surface and then secreting protons into an extracellular compartment formed between osteoclast and bone surface. This secretion is necessary for bone mineral solubilization and the digestion of organic bone matrix by acid proteases.

The primary mechanism responsible for acidification of the osteoclast-bone interface is vacuolar h+-Adenosine triphosphatase (atpase) coupled with cl− conductance localized to the ruffled membrane.

Carbonic anhydrase II (CAII) provides the proton source for extracellular acidification by H+-atpase and the HCO3− source for the HCO3−/cl− exchanger. Whereas some transporters are responsible for the bone resorption process, others are essential for ph regulation in the osteoclast.

The Ph regulation in Osteoclasts

Page 61: Metabolic bone disease remodeling sequences

The osteoclast acidifies the resorption lacunae by active secretion of protons through a V-ATPase, which is followed by passive transport of chloride ions, thereby maintaining electroneutrality.

The chloride channel ClC-7 is responsible for this process.

Mutations or inhibition of either ClC-7 or the V-ATPase will lead to reduced acidification and therefore inhibition of bone resorption.

The disruption of ClC-7 and loss of function mutations in the a3

subunit of the VATPase leads to a defect in bone degradation, resulting in a severe form of osteopetrosis, which leads to an increase in the bone mass.

Calcitonin has long been known to suppress bone resorption

inhibiting the activity of osteoclasts. However, the exact mode of action of calcitonin is still unknown. Preliminary data suggest that calcitonin may be the long sought physiology modulator of intracellular pH in the osteoclasts.

Page 62: Metabolic bone disease remodeling sequences

The Ph regulation in Osteoclasts

The HCO3−/cl− exchanger, in association with CAII, is the major transporter for maintenance of normal intracellular ph. An na+/H+ antiporter may also contribute to the recovery of intracellular ph during early osteoclast activation.

Once this mechanism has been rendered inoperative, another conductive pathway translocates the protons and modulates cytoplasmic ph.

Inward-rectifying K+ channels may also be involved by compensating for the external acidification due to H+ transport.

These different effects of transport processes, either on bone resorption or ph homeostasis, increase the number of possible sites for pharmacological intervention in the treatment of metabolic bone diseases.

Page 63: Metabolic bone disease remodeling sequences

Osteoclasts resorb bone by generating a pH gradient between the cell and bone surface . An acidic pH favors the dissolving of the bone mineral (hydroxyapatite) in the resorption lacuna revealing the organic collagen network.

Carbonic anhydrase II (CA II) is a cytoplasmic enzyme hydrolyzing carbon dioxide into bicarbonate and protons . CA II is the main source of protons for the acidification of the resorption lacuna . A vacuolar-type proton pump, V-ATPase, is present in high amounts in the membranes of a population of intracellular vesicles. V-ATPase transports the protons generated by CA II into these vesicles, which are then transported and fused to the RB membrane releasing their proton content to the lacuna.

.Carbonic anhydrase II (CA II)

Page 64: Metabolic bone disease remodeling sequences

Acidification of the extracellular resorption lacuna is completed by passive, potential-driven chloride transport . RB thus contains large amounts of V-ATPase, which probably continues to function by transporting protons directly from the cytoplasm to the lacuna.

Hydroxyapatite is first solubilized in the acidified lacuna, after which various proteolytic enzymes, such as lysosomal enzymes and bone-derived collagenases secreted by osteoclasts through RB, digest the exposed organic matrix. When the osteoclast stops resorption and moves away from the resorption lacuna, phagocytes clean up the remains and make room for osteoblasts to begin bone formation in the newly formed resorption cavity.

Carbonic anhydrase II (CA II)

Page 65: Metabolic bone disease remodeling sequences

Osteoclast apoptosis

Page 66: Metabolic bone disease remodeling sequences

OPG as Decoy

• The pre-osteoblasts matures into osteoblasts, which stop making RANK-L, and start secreting OPG (osteoprotegerin) The OPG binds to RANK-L acts as a decoy receptor, thus block the activation of Osteoclasts.

Page 67: Metabolic bone disease remodeling sequences

Regulation of osteoclastic bone resorptionRole of Genes

A balance between bone formation and bone resorption is a necessity for the normal function of bone. Although many acquired or environmental factors are known to affect the adult bone mineral density (BMD), genetic factors play a major role as determinants of variation in BMD . It has been estimated that up to 80% of BMD is genetically controlled, and it is the rate of bone formation rather than the rate of bone resorption that is influenced by genes .

Page 68: Metabolic bone disease remodeling sequences

Regulation of osteoclastic bone resorption

• Systemic stimulators of bone resorption include PTH, interleukin-1, tumor necrosis factor , transforming growth factor α and 1,25-dihydroxyvitamin D3 .

• PTH and D3 stimulate bone resorption by increasing the activity of existing osteoclasts and by promoting the differentiation of osteoclast precursors into mature multinucleated osteoclasts and D3 or other vitamin D metabolites seem to play a role in the correction of calcium malabsorption,

• Osteoblasts mediate the effects of PTH and D3 on the osteoclasts . Calcitonin, regulates blood calcium and phosphate levels by causing short-lived falls in the plasma calcium. It does that by its effects to inhibit osteoclastic bone resorption and to promote renal calcium excretion .

• Calcitonin, gamma interferon and transforming growth factor β are extremely potent in inhibiting osteoclast differentiation and activity.

Page 69: Metabolic bone disease remodeling sequences

OPG• Osteoprotegerin is a soluble protein member of

TNF family • Produced by bone , hematopoetic marrow ,

immune cells • OPG blocks action of RANKL , inhibits

osteoclastogenesis by acting as a decoy receptor that binds to RANKL , thus preventing interaction between RANK & RANKL

• Therefore interplay between bone cells & these molecules permits osteoblasts and stromal cells to control osteoclasts development.

Page 70: Metabolic bone disease remodeling sequences

Bone Resorption

Page 71: Metabolic bone disease remodeling sequences

Reversal Phase

• During the reversal phase macrophages may appear on the resorption surface. The roles of these macrophages are not known, but it has been suggested that they complete the task of bone resorption. Alternatively, they might produce factors that help initiate osteoblastic bone formation. If the fate of osteoclasts at the reversal site is apoptosis, the function of macrophages could be related to destruction of osteoclast corpses.

Page 72: Metabolic bone disease remodeling sequences

Coupling mechanism• The mechanism by which osteoblasts are summoned

into the resorption lacuna is uncertain, but it is probable that a number of paracrine factors produced in or around the remodeling site are involved. These “coupling factors” could be elaborated by cells involved in the activation of resorption (lining cells) or by osteoclasts themselves or some other cell types present in the resorption lacunae. The factors could also be released from the bone matrix during the resorption phase. Osteoclasts are highly motile and actively migrating cells, so that after completion of one resorption lacuna, they can move along the bone surface to another site and restart the resorption phase.

Page 73: Metabolic bone disease remodeling sequences

The coupling factor is derived from growth factors such as IGF-I and -II and TGF-β that are released by osteoclastic proteolytic digestion of bone matrix during bone resorption, and are thus made available for stimulating osteoblast precursors to form osteoblasts and new bone.

Osteoclasts secrete anabolic growth factors that mediate osteoblast chemotaxis, proliferation, differentiation, and mineralization. Some of the osteoclast-secreted factors that may enhance osteoblast activity include TGF-β , IGF-1, TRAP (tartrate-resistant acid phosphatase), and BMPs.

“coupling factor” – Change over

Page 74: Metabolic bone disease remodeling sequences

Maturation of Osteoblasts

Creeping of Osteoblast

Page 75: Metabolic bone disease remodeling sequences
Page 76: Metabolic bone disease remodeling sequences
Page 77: Metabolic bone disease remodeling sequences

• The mature osteoblasts secrete osteoid and then mineralize it to fill in the cavity in 3 – 4 months.

• The matrix also contains other proteins and growth factors such as IGF and TGF-b

• During mineralization and filling of the cavity, some osteoblasts turns into osteocytes, some into lining cells, and the rest undergo apoptosis.

Page 78: Metabolic bone disease remodeling sequences

Bone Formation

• Bone formation is a two-stage process beginning with the deposition of osteoid, an organic matrix consisting primarily of type I collagen and various other components. In normal adult bone, osteoid is laid down in discrete lamellae about 3 m thick. The second stage in bone formation is mineralization of the organic matrix, which occurs after a delay of about 20 days called the mineralization lag time. 

Page 79: Metabolic bone disease remodeling sequences

Nucleation - theory• The nucleation theory holds that the type I collagen

fibril is the major site of crystal nucleation where calcium phosphate crystals are deposited in the hole regions of these fibrils.

• Originally it was believed that the initiation of bone mineralization is mainly an extracellular, biochemical process where the presence of collagens, certain glycosaminoglycans or lipids could trigger the initiation of calcification.

• The first line of evidence that cellular activity might be needed for the mineralization of bone arose out of the finding that mitochondria accumulate calcium. Later it was shown that mitochondria of bone-forming cells might produce a local rise in the levels of mineral ions, and also a matrix, which was capable of being mineralized.

Page 80: Metabolic bone disease remodeling sequences

Matrix - theory• The matrix vesicles theory states that bone-forming

cells produce small 100-200 nm in diameter organelles that have been observed in mineralizing tissues and cell cultures, often in contact with the initial mineral crystals

• These vesicles have high alkaline phosphatase, alkaline pyrophosphatase and ATPase content, but hardly any acid phosphatase, and are thus not lysosomal origin.

• Plausible evidence has been demonstrated to support the matrix vesicle theory, showing that membrane bound vesicles bud from the long processes of osteoblastic cells and that the mineralization is induced by the release of Ca2+-containing vesicles.

Page 81: Metabolic bone disease remodeling sequences

Osteonectin

• Osteonectin is a glycoprotein in the bone that binds calcium. It is secreted by osteoblasts during bone formation, initiating mineralization and promoting mineral crystal formation. Osteonectin shows affinity for collagen in addition to bone mineral calcium.

• Osteonectin increases the production and activity of matrix metalloproteinases, a function important to invading cancer cells within bone.

• Over expression of osteonectin is reported in many human cancers such as breast, prostate and colon.

• Additional functions of osteonectin beneficial to tumor cells include angiogenesis, proliferation and migration.

Page 82: Metabolic bone disease remodeling sequences

Mineralization

• However, later it has been speculated that the two mechanisms for bone mineralization are not alternative but parallel; one is predominant in both calcified cartilage and primitive woven bone, the other in lamellar bone.

• • The rate of mineralization in both woven bone and in

lamellar bone seems to depend on the presence of inhibitor molecules (e.g. pyrophosphate and acidic NCPs), which in solution seem to regulate the kinetics of the mineralization process. The cell buds off organelles capable of mineral accumulation and then synthesizes proteins that can control the rate at which crystallization proceeds

Page 83: Metabolic bone disease remodeling sequences
Page 84: Metabolic bone disease remodeling sequences

Mineralization

• After the mineralization process is triggered, the mineral content of the matrix increases rapidly over the first few days to 75% of the final mineral content (primary mineralization), but it takes from 3 months up to a year for the matrix to reach its maximum mineral content (secondary mineralization). The principal component of the mature mineral phase is hydroxyapatite.

Page 85: Metabolic bone disease remodeling sequences

Formation of lining cells and mature osteocytes

Page 86: Metabolic bone disease remodeling sequences

Osteocytes

Page 87: Metabolic bone disease remodeling sequences

The newly formed osteocytes re-establish its network with the surrounding osteocytes and lining cells.

Page 88: Metabolic bone disease remodeling sequences

calcium phosphates were formed through a multistage assembly process, during which an initial amorphous phase DPCD was followed by a phase transformation into a crystalline phase and then the most stable hydroxyapatite (HAp). This provided new insights into the template−biomineral interaction and a mechanism for biomineralization. The complete maturation of the newly form matrix takes about 3 years.

Maturation of Mineralization

Page 89: Metabolic bone disease remodeling sequences
Page 90: Metabolic bone disease remodeling sequences

Mineralization - Inorganic pyrophosphate

• The regulation of mineralization relies largely on inorganic pyrophosphate, which inhibits abnormal calcification.

• It is a very small molecule, but it is an important inhibitor of calcification.

• It is involved in controlling the right rate, the right pace of calcification in the normal skeleton.

• Levels of this important bone regulator are controlled by at least three other molecules: nucleotide pyrophosphatase phosphodiesterase 1 (NPP1), which produces pyrophosphate outside the cells; ankylosis protein (ANK), which further contributes to the extracelluar pool of pyrophosphate by transporting it from the cell's interior to the cell surface; and tissue nonspecific alkaline phosphatase (TNAP), which breaks down pyrophosphate in the extracellular environment, keeping its levels in check.

Page 91: Metabolic bone disease remodeling sequences

DISCLAIMER.• It is intended for use only by the students of orthopaedic surgery. • Many GIF files are taken from Internet.• Views and opinion expressed in this presentation are personal opinion..• For any confusion please contact the sole author for clarification.• Every body is allowed to copy or download and use the material best suited

to him. I am not responsible for any controversies arise out of this presentation.

• For any correction or suggestion please contact [email protected] INFORMATION

All animation slides are taken from, “Osteoporosis and Bone Physiology” web site, 1999 - 2006 http://courses.washington.edu/bonephys of Dr. Susan Marie Ott, MD. Medical staff of University of Washington Medical Center.

And the summary of BMU mechanism is based on the thesis“Attachment, polarity and communication characteristics of bone cells”Joanna IlvesaroDepartment of Anatomy and Cell Biology and Biocenter Oulu, P.O. B. 5000, FIN-90014 University of Oulu, Finland, http://herkules.oulu.fi/isbn9514259351/html/index.html